Jefferies Financial Group’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$81.3M Sell
1,500,000
-300,113
-17% -$13.5M 0.6% 27
2026
Q2
$75.7M Buy
1,800,113
+1,049,292
+140% +$33.4M 0.5% 29
2026
Q1
$19.8M Buy
+750,821
New +$22M 0.14% 120
2025
Q1
– Sell
-8,615
Closed -$203K – 1602
2024
Q4
$203K Sell
8,615
-27
-0.3% -$664 ﹤0.01% 1379
2024
Q3
$221K Buy
+8,642
New +$220K ﹤0.01% 1203
2023
Q4
– Sell
-70,308
Closed -$1.96M – 1683
2023
Q3
$1.96M Buy
+70,308
New +$2.3M 0.02% 631
2023
Q1
– Sell
-9,055
Closed -$256K – 1613
2022
Q4
$256K Buy
+9,055
New +$287K ﹤0.01% 1232

Other funds holding ARKG

Jefferies Financial Group's ARKG Position: Q3 2026 in Review

Jefferies Financial Group reduced its ARK Genomic Revolution ETF (ARKG) stake by 17% in Q3 2026, selling an estimated $13.5M and leaving 1,500,000 shares worth $81.3M. The position accounts for 0.6% of the portfolio, ranked #27.

Jefferies Financial Group first reported a position in ARKG in Q4 2022 and has held it in 7 quarters since. 316 funds tracked by Wall St. Rank hold ARKG as of Q3 2026.

  • Jefferies Financial Group held 1,500,000 shares of ARK Genomic Revolution ETF worth $81.3M as of Q3 2026.
  • Jefferies Financial Group sold 300,113 ARK Genomic Revolution ETF shares in Q3 2026, an estimated $13.5M.
  • ARK Genomic Revolution ETF made up 0.6% of Jefferies Financial Group's portfolio in Q3 2026, its #27 holding.
  • Jefferies Financial Group first reported a position in ARK Genomic Revolution ETF in Q4 2022 and has held it in 7 quarters since.
  • 316 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2026.

Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.